All In Biotech

Drug Trial Radar · NCT07683793

A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants

An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Dec 9, 2026

Study completion Dec 9, 2026

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study evaluates the effect of pantoprazole (a proton pump inhibitor) on the pharmacokinetics (PK) of CHF10196 (Florensocatib) in healthy male participants. Participants receive CHF10196 alone and in combination with pantoprazole to assess potential drug-drug interaction (DDI) effects on systemic exposure.

Conditions

  • Healthy Volunteers

Interventions

  • CHF10196Drug

    Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13

  • PantoprazoleDrug

    Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameter: AUC0-∞Time frame: pre-dose up to 168 hours post-dose
  2. PK parameter: AUC0-tTime frame: pre-dose up to 168 hours post-dose
  3. PK parameter: CmaxTime frame: pre-dose up to 168 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit (CRU) Limited

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.